Synvista Therapeutics, Inc. (SYNI)

Synvista Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2007	FY 2006	FY 2005	FY 2004	FY 2003
Period Ending	Sep 30, 2008	Dec 31, 2007	Dec 31, 2006	Dec 31, 2005	Dec 31, 2004	Dec 31, 2003
Cash & Equivalents	7.96	15.65	1.48	6.58	11.18	16.68
Cash & Short-Term Investments	7.96	15.65	1.48	6.58	11.18	16.68
Cash Growth	-54.00%	958.05%	-77.54%	-41.10%	-32.99%	-4.36%
Prepaid Expenses	0.44	0.23	0.26	0.22	-	-
Other Current Assets	-	-	0.05	-	0.16	0.23
Total Current Assets	8.4	15.88	1.79	6.8	11.34	16.9
Property, Plant & Equipment	0.03	0.02	0.01	0.06	0.11	0.1
Long-Term Investments	-	0.4	-	-	-	-
Long-Term Deferred Charges	-	-	-	0.13	-	-
Other Long-Term Assets	0.33	0.41	0.5	0.15	0.2	0.25
Total Assets	8.75	16.71	2.31	7.13	11.64	17.25
Accounts Payable	0.76	1.5	0.81	0.35	0.59	0.47
Accrued Expenses	1.03	0.46	0.25	0.79	2	1.4
Other Current Liabilities	2.38	0.88	-	-	-	-
Total Current Liabilities	4.17	2.84	1.06	1.14	2.6	1.87
Total Liabilities	4.17	2.84	1.06	1.14	2.6	1.87
Common Stock	0.03	0.03	0.03	0.58	0.48	0.4
Additional Paid-In Capital	282.55	276.83	244.36	228.23	214.27	202.6
Retained Earnings	-278.1	-263.09	-243.15	-222.81	-205.71	-187.62
Total Common Equity	4.48	13.77	1.24	5.99	9.05	15.38
Shareholders' Equity	4.58	13.87	1.24	5.99	9.05	15.38
Total Liabilities & Equity	8.75	16.71	2.31	7.13	11.64	17.25
Net Cash (Debt)	7.96	15.65	1.48	6.58	11.18	16.68
Net Cash Growth	-54.00%	958.05%	-77.54%	-41.10%	-32.99%	-4.36%
Net Cash Per Share	3.08	6.05	0.81	5.71	12.60	23.04
Filing Date Shares Outstanding	2.59	2.59	2.59	1.16	1.16	0.81
Total Common Shares Outstanding	2.59	2.59	2.59	1.16	0.97	0.81
Working Capital	4.23	13.04	0.73	5.66	8.74	15.03
Book Value Per Share	1.73	5.32	0.48	5.17	9.33	19.01
Tangible Book Value	4.48	13.77	1.24	5.99	9.05	15.38
Tangible Book Value Per Share	1.73	5.32	0.48	5.17	9.33	19.01
Machinery	-	0.41	0.4	0.4	0.39	0.3
Leasehold Improvements	-	0.01	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.